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Abstract 
Background. Poisoning with methanol and ethylene glycol can cause serious 
morbidity and mortality. Specific treatment involves the use of antidotes 
(fomepizole or ethanol) with or without extracorporeal elimination techniques. 
Methods. A prospective audit of patients with methanol or ethylene glycol 
poisoning reported by telephone to the National Poisons Information Service 
(NPIS) in the United Kingdom (UK) was conducted during the 2010 calendar 
year and repeated during the 2012 calendar year. The study was conducted  
to determine the frequency of clinically significant systemic toxicity and 
requirement for antidote use and to compare outcomes and rates of adverse 
reaction and other problems in use between ethanol and fomepizole.  
Results. The NPIS received 1315 enquiries involving methanol or ethylene 
glycol, relating to 1070 individual exposures over the 2-year period. Of 548 
enquiries originating from hospitals, 329 involved systemic exposures (enteral 
or parenteral as opposed to topical exposure), of which 216 (66%) received 
an antidote (204 for ethylene glycol and 12 for methanol) and 90 (27%) 
extracorporeal treatment (86 for ethylene glycol and 4 for methanol). 
Comparing ethanol with fomepizole, adverse reactions (16/131 vs 2/125, P < 
0.001) and administration errors, lack of monitoring or inappropriate use 
(45/131 vs. 6/125, P<0.0001) were reported more commonly, while non-
availability and inadequate stocks were reported less commonly (6/125 vs 
33/131, P < 0.0001). There were 8 fatalities and complications or sequelae 
occurred in 21 patients. Poor outcome (death, complications or sequelae) was 
significantly associated with older age, higher poisoning severity scores and 
lower pH on admission (p<0.001).  
Conclusions. Systemic poisoning with ethylene glycol or methanol results in 
hospitalisation at least 2-3 times per week on average in the UK. No 
difference in outcome was detected between ethanol and fomepizole-treated 
patients, but ethanol was associated with more frequent adverse reactions. 
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Background 
Methanol and ethylene glycol are present in a number of commercial products 
available to the public, including antifreeze, brake fluids and solutions for 
wallpaper stripping, window-cleaning and windscreen-washing. Sporadic 
outbreaks such as an episode of mass methanol poisoning from consumption 
of illegal spirits in Estonia1 and ethylene glycol poisoning from contaminated 
water systems2 have also been reported.  
 
Although infrequent, systemic poisoning with methanol and ethylene 
glycol is important because it can cause severe toxicity and, if untreated, is 
associated with serious morbidity such as renal failure and neurological 
sequelae, mediated by toxic metabolites formed via alcohol dehydrogenase.3 
These complications can be prevented by administration of the antidotes 
ethanol or fomepizole, which block alcohol dehydrogenase, but availability of 
these antidotes is inconsistent in hospitals across the United Kingdom (UK) 
and also in other countries.4 Limited information is available about the 
frequency and management of these poisonings in the UK and in the 
comparative benefits and adverse effects of antidotes.  This information is 
needed for planning of services including provision of antidotes and renal 
replacement therapy.  
 
A prospective audit of cases of methanol and ethylene glycol poisoning 
reported through telephone enquiries to the National Poisons Information 
Service (NPIS) was therefore conducted during the 2010 calendar year. Its 
aims were to determine the frequency of potentially serious methanol and 
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ethylene glycol poisoning in the UK requiring treatment with an antidote and/or 
haemodialysis, the availability, appropriate clinical use and adverse reactions 
to antidotes and the frequency of indicators of adverse clinical outcomes, 
including death, requirement for ITU or HDU admission, haemodialysis etc. 
The study was repeated during 2012 to increase the number of patients 
studied, especially those treated with fomepizole as only a small number were 
collected in 2010.  This repeated study also provided additional information on 
trends in the frequency, management and outcomes of systemic ethylene 
glycol and methanol poisoning to guide future strategies for improving patient 
management, including availability of antidotes and laboratory assays. 
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Methods 
All telephone enquiries relating to products containing ethylene glycol  and/or 
methanol made by UK health professionals to any of the 4 units of the 
National Poisons Information Service (NPIS), located in Birmingham, Cardiff, 
Edinburgh and Newcastle, were considered for inclusion in the study 
prospectively over two annual periods which were the complete calendar 
years for 2010 and 2012.  The study population was defined as patients with 
suspected significant systemic exposures to ethylene glycol and methanol 
who were admitted to hospital. Significant systemic exposure was defined as 
a potential systemic exposure to a toxic dose of ethylene glycol or methanol, 
according to UK treatment guidance (adult ≥10g adult; child 0.1g/kg), where 
clinical features of toxicity were present and/or where use of an antidote 
and/or or extracorporeal treatment was recommended by NPIS. Cases were 
considered for eligibility at the time of the enquiry by specialists in poisons 
information (SPI) using a pre-defined protocol.  
Enquiries from out-of-hours general practitioners (GPs), publically 
available telephone helplines such as National Health Service (NHS) Direct 
and other non-hospital sources which did not lead to hospital attendance were 
excluded from the study as these sources do not provide follow up information 
and patients with significant exposure will subsequently be referred to 
hospital.  
For patients attending hospitals, telephone follow-up of eligible cases 
was attempted by the SPI within 4-8 hours of the initial enquiry and repeated 
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daily until discharge from hospital. If this failed, a follow-up by letter was sent 
to the responsible clinician.  
Details of all calls and information from follow-up were entered 
contemporaneously as free text into the United Kingdom Poisons Information 
Database (UKPID), the national database in which clinical data from NPIS 
enquiries is recorded. Data fields in UKPID included enquiry date/time, patient 
age and sex, type of caller, source of enquiry, location and circumstances of 
exposure, product (ingredients, amount, route of exposure, duration and time 
since exposure), clinical features, WHO/IPCS/EC/EAPCCT Poisoning 
Severity Score (PSS)5, investigations and treatments prior to enquiry, 
treatments recommended and outcome. In addition to these routinely 
collected data, the protocol specified other clinically-relevant information to be 
recorded for use in the study, including the timing of antidote and/or 
extracorporeal treatment, description of adverse drug reactions and the 
results of biochemical investigations when available (ethylene glycol and 
methanol concentrations, ethanol concentration, Na+, K+, Cl-, HCO3-, pH, 
lactate, osmolality, osmolal gap, anion gap). These details were entered as 
free text in the UKPID record. Final outcomes of follow-up were recorded as 
complete recovery, sequelae (defined as complication of poisoning persisting 
at the time of last follow-up), death or unknown. All enquiries and all follow-up 
data were checked by a SPI (CG) and a clinical toxicologist (RT). Follow-up 
data received up to 31st May 2013 were used in the analysis, with 
consolidation of multiple enquiries about the same patient into a single record.  
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Data relating to the study population were transferred into an Excel 
spreadsheet for analysis. Descriptive data are reported as means (with 
standard deviation) or medians (with range). Comparative continuous 
variables were compared using unpaired t-test (for normally distributed data) 
and Mann Whitney U test (for non-normally distributed data). Statistical 
analysis was performed using SPSS V 21(Chicago, IIlinois). 
 
Causality assessment of reported adverse reactions to ethanol and 
fomepizole was performed independently using the Naranjo Adverse Drug 
Reaction Probability Scale by two clinical pharmacologists and toxicologists 
with experience of assessing adverse drug reactions (RT & ST). 
   
A national toolkit provided by the Health Research Authority in the 
United Kingdom (http://www.hra-decisiontools.org.uk/ethics/) indicates that  
approval from a Research Ethics Committee is not required for studies that 
use information collected routinely in any UK administration (England, Wales, 
Scotland, Northern Ireland) as part of usual clinical care, provided this 
information is passed to the researchers in a fully anonymised format.       
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Results 
During the 2 years of the study, of 101,594 telephone enquiries made to the 
NPIS in total, 1315 (1.3%) concerned suspected exposure to ethylene glycol 
or methanol, involving 1070 individual exposures. These included 418 
enquiries related to specifically to ethylene glycol and 28 to methanol, with the 
remaining enquiries about household products where the ingredients were not 
specified but ethylene glycol or methanol may have been included.   
Non-hospital sources contributed 522 enquiries and there were a 
further 219 enquiries about topical exposures or systemic exposures unlikely 
to cause toxicity which were not followed up, leaving 329 systemic exposures 
eligible for study follow-up. In 71 cases, follow-up was not attempted or failed 
due to the enquirer not being contactable or declining to provide information, 
leaving a final study population of 258 cases (243 ethylene glycol and 15 
methanol exposures) studied in detail.  
 
In 34 cases, patients were discharged without requiring any specific 
treatment. Including these, outcomes at hospital discharge or death were 
known for 194 of the 329 systemic exposures (59%) and for 160 of 224 
patients (71%) who received an antidote or extracorporeal treatment. (Figure 
1) 
 
An antidote was administered to 216 patients overall, with suspected 
exposure to ethylene glycol in 204 and to methanol in 12. Overall, 91 received 
ethanol alone, 85 fomepizole alone, and 40 both antidotes. There was no 
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difference in the PSS between those treated with ethanol (PSS 0-1 in 
62/131(47%), PSS 2-3 in 66/131(50%) and unknown in 3) and fomepizole 
(PSS 0-1 in 56/125(45%), PSS 2-3 in 68/125(54%) and unknown in 1). 
Analytical confirmation of exposure was available in 106 cases (49%, ethylene 
glycol 101, methanol 5) and unavailable in 81 (38%) cases. In the remaining 
29 (13%) cases, although antidote treatment was initiated, plasma 
concentrations were found subsequently to be below the limits of detection for 
both ethylene glycol and methanol and the antidote was discontinued.  
 
Ethylene glycol exposures 
204 of the 243 (84%) suspected ethylene glycol exposures reviewed were 
treated with an antidote: 83 received ethanol alone, 81 fomepizole alone and 
40 both antidotes. Fomepizole was used as the sole antidote in 12 patients 
with ethylene glycol concentrations >500 mg/L (median 1100, range 584-
2140), all of whom made a complete recovery without extracorporeal 
treatment.   The pattern of antidote use for ethylene glycol poisoning, PSS 
score and ethylene glycol concentrations by treatment group are shown in 
Table 1. Fomepizole was used more commonly than ethanol in patients with 
PSS score 3 (43/61, 70.5% vs 32/61, 52.4%, P<0.05). There were no 
significant differences in outcome between patients treated with different 
antidotes overall or in a subgroup of more severely poisoned patients (PSS 2-
3) in whom 6/36 (17%) treated with ethanol only and 6/42(14%) treated with 
fomepizole only developed sequelae or died. Fomepizole was used for a 
greater proportion of ethylene glycol cases in 2012 (83/112, 74.1%) compared 
with 2010 (48/92, 52.2%; P<0.01). 
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Haemodialysis and/or other extracorporeal elimination therapies were 
used in 86 patients with suspected ethylene glycol exposure, without antidotal 
treatment in 7 cases and in conjunction with antidotes in 78. In 1 patient who 
subsequently died, it is not known whether antidotal treatment was 
administered. More than 1 extracorporeal treatment modality was used in 6 
patients and there were no reported adverse events. The type of 
extracorporeal treatment used for ethylene glycol poisoning, PSS score and 
ethylene glycol concentrations are shown in Table 2. 
 
There were 5 suspected ethylene glycol related deaths reported in the 
2 years studied. In 3 cases, analytical confirmation of ethylene glycol 
exposure was available and deaths were likely to be due directly to ethylene 
glycol poisoning. These included: a 35-year old presenting with coma, severe 
metabolic acidosis (pH 7.13), renal failure (creatinine 220 µmol/L) and 
ethylene glycol concentration 1935 mg/L; a 33-year old presenting with coma, 
severe metabolic acidosis (pH 7.14), broad complex tachycardia and ethylene 
glycol concentration 2010 mg/L who developed cerebral oedema and a 59-
year old presenting with profound metabolic acidosis (pH 6.85) and acute 
renal failure (creatinine 525 µmol/L). In the other 2 cases, the cause of death 
was unclear. Both antidote and extracorporeal treatments were instituted in 4 
patients and antidote treatment only in 1 case.  
 
Complications or sequelae were reported in 21 of the 155 ethylene 
glycol cases with a recorded outcome, with analytical confirmation of ethylene 
glycol exposure in 16 of these cases, concentrations below the limit of 
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detection in 3 cases and unknown in 2 cases. Renal impairment was reported 
in 20 of these 21 cases at the time of the last follow-up. Sequelae included 
upper cranial nerve palsy and peripheral neuropathy following intensive care 
admission for aspiration pneumonia and haemodialysis for acute renal failure 
(creatinine >1000 µmol/L).  A 26-year-old man admitted unresponsive with a 
pH of 6.68 and ethylene glycol concentration of 133 mg/L developed acute 
renal failure which resolved, but he had residual cognitive impairment, visual 
disturbances, refractory seizures and dystonia. MRI findings typical of 
ethylene glycol poisoning, including low attenuation of the thalamus, basal 
ganglia, bilateral temporal lobes and occipital lobes, were present.   
 
Patients who died or developed complications or sequelae from 
ethylene glycol poisoning were older, had significantly higher poisoning 
severity scores and lower pH on admission than those who made a complete 
recovery, but the plasma concentrations of ethylene glycol were not 
significantly different between the two groups (Table 3).  
 
Methanol exposures 
12 of the 15 (80%) suspected methanol exposures reviewed were treated with 
an antidote: 8 received ethanol alone (oral ethanol in 2, intravenous ethanol in 
5, both oral and intravenous ethanol in 1) and 4 fomepizole. Fomepizole was 
used as the sole antidote without extracorporeal treatment in 1 patient with a 
methanol concentration of 1627 mg/L who subsequently made a full recovery. 
In addition to antidote treatment, haemofiltration was used in 3 patients and 
haemodiafiltration in 1 patient. There were 3 suspected methanol related 
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deaths reported during the 2 year period, but analytical confirmation was only 
available in 1 patient who had a methanol concentration of 3462 mg/L and an 
admission pH of 6.6 who died despite treatment with intravenous ethanol and 
haemofiltration.   
 
Adverse reactions to antidotes 
Adverse reactions to antidotes were reported in 18 patients treated for 
ethylene glycol poisoning and none treated for methanol poisoning. Of these, 
11 were treated with ethanol, 2 with fomepizole and 5 with both antidotes. Of 
19 adverse reactions reported in 16 (13%) ethanol-treated patients there were 
12 reactions in 11 ethanol-treated patients classified as probably related to 
ethanol use. These consisted of intoxication (7), reduced conscious level (2), 
nausea and vomiting (1), slurred speech (1), and acute alcohol withdrawal (1). 
There were 7 reported adverse reactions in another 6 ethanol-treated patients 
classified as possibly related to ethanol use, which were vomiting (3), nausea 
(1), drowsiness (1), agitation (1) and headache (1). Adverse reactions were 
less commonly reported after fomepizole than ethanol use (2/125 vs 16/131, P 
< 0.001). The 2 reactions were both classified as possibly related to 
fomepizole. One patient had a period of shaking which was treated 
supportively with full recovery. The cause was uncertain and may have been 
alcohol withdrawal. Another patient developed angio-oedema which resolved 
after fomepizole was discontinued and the patient made a full recovery.  
 
Other reported problems associated with antidote use included lack of 
availability, inadequate monitoring and administration errors (Table 4). Non-
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availability and inadequate stocks were reported more commonly with 
fomepizole than ethanol (33/125 vs. 6/131, P<0.0001) but administration 
errors, lack of monitoring or inappropriate use were more commonly reported 
with ethanol than fomepizole (45/131 vs. 6/125, P<0.0001).  
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Discussion 
Systemic poisoning with ethylene glycol (or less commonly methanol) is 
uncommon, but these data indicate that there are least 2-3 cases per week 
across the UK. These presentations are associated with significant morbidity 
and death occurs in an important minority.  
 
The poisoning severity score and pH on admission appear to be 
predictors of mortality and morbidity. A previous retrospective study has 
suggested that a high osmolal gap and anion gap and a low pH (<7.22) were 
associated with increased mortality in toxic alcohol/glycol poisoning6 and 
another study in methanol poisoning showed that coma (GCS<8) and low pH 
(<7.2) were predictors of poor outcome.7 The actual values for the osmolal 
gap and anion gap were recorded in only a small number of cases in the 
current study as a result of enquirers being unable to supply specific 
information, especially chloride, bicarbonate or plasma osmolality results; this 
precluded calculation of these parameters and further analysis.    
 
There is marked variability in the management of toxic alcohol 
exposures in the UK, particularly with respect to use of antidotes. The study 
suggested that fomepizole is associated with fewer adverse reactions and 
problems with administration or monitoring compared with ethanol. Adverse 
events and difficulty in maintaining therapeutic concentrations of ethanol have 
previously been reported in other studies.8,9  Nevertheless, the outcome was 
generally favourable, irrespective of the antidote used, even in a subgroup of 
patients with more severe symptoms (PSS 2-3). Although some benefits were 
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seen with fomepizole in a study involving dogs10, there have been no 
randomised controlled trials comparing fomepizole with ethanol in humans but 
a recent systematic review concluded that there are no significant differences 
in outcome.11 A statistically significant difference in mortality in a sub-group of 
patients with low pCO2 was reported in a small study of methanol-poisoned 
patients when treated with fomepizole.7 A recent study in a mass poisoning 
outbreak of methanol found no differences in overall clinical effectiveness 
between fomepizole and ethanol but there was no comparison in sicker 
patients in this study.12 
 
Fomepizole without extracorporeal removal was used in 13 patients 
with ethylene glycol or methanol concentrations exceeding 500 mg/L and 
there was complete recovery in all cases. Recent evidence suggests that 
fomepizole may obviate the need for haemodialysis in selected cases,13 but 
the cost-effectiveness of this treatment strategy is controversial depending on 
the local cost of intensive care and dialysis over a short period compared to a 
more prolonged course of fomepizole.14 
 
In the UK, joint College of Emergency Medicine/NPIS guidelines on 
antidote stocking in acute hospitals recommend fomepizole as the antidote of 
choice for toxic alcohol and glycol poisoning, but an audit conducted in 
parallel to this study in 2010 showed that only around 20% of acute hospitals 
in the UK stocked this antidote.4 The present study has suggested a small 
increase in the use of fomepizole between 2010 and 2012. Although lack of 
on-site availability was only reported and documented in 16 cases, this is 
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likely to be an underestimate as generally the preferential use of ethanol 
suggests that fomepizole was not immediately available in many cases.  
 
Although limited evidence suggests that haemodialysis is more 
effective at removing ethylene glycol and methanol, continuous renal 
replacement methods such as continuous haemofiltration or haemodiafiltration 
are used frequently due to non-availability of on-site dialysis in many intensive 
care units in the UK.  
 
Assays for methanol and ethylene glycol are only available on a 24 
hour basis in a few hospitals in the UK and antidote treatment is often 
provided before the results become available. In this study, antidote was 
administered in 33 patients before methanol or glycol concentrations were 
reported as undetectable.  Such unnecessary use could be reduced by more 
complete and rapid availability of plasma concentration measurements. 
Poisoning with methanol and ethylene glycol is too uncommon to justify 
appropriate assays being provided in all acute hospitals, but these analytical 
resources need to be available quickly when exposure is suspected. 
Development of cheap, rapid and effective screening detection methods is 
also needed to avoid missing these potentially serious cases.  
 
Better methods of organising assays and antidote supply are needed, 
with resources available on a regional or supraregional basis and a 
mechanism of distributing costs between hospitals sharing these services.15 
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Further studies are also needed to monitor the availability of antidotes and 
extracorporeal treatments and the impact of recent guidelines. 
 
Although this is the largest cohort of toxic alcohol exposures reported in 
the UK, the study has a number of limitations. It was not possible to examine 
the patients’ medical records; data were obtained by telephone follow-up, so 
inaccuracies or omissions cannot be excluded; detailed follow-up and 
outcome data were obtained in only 59% of eligible cases and 71% of those 
receiving antidotal and/or extracorporeal treatments due to difficulties in 
tracking patients moving through different clinical environments during their 
hospital stay or refusal to provide patient data over the telephone.  We cannot 
exclude the possibility that outcomes might differ between patients where data 
is available compared to those where it is not. All cases of poisoning in the UK 
are not referred to NPIS and those not referred cannot be included in this 
study, thereby potentially underestimating the number of cases and 
consequent complications and adverse events.  Hospital episode statistics 
data for England in 2011-2, however, report a total of 112 hospital admissions 
attributable to toxic effects of methanol (28), glycols (25) and other alcohols 
(59). Although these data may be affected by inaccuracies in coding, these 
statistics for England are consistent with the number of annual numbers of 
cases reported to the NPIS from across the UK in this study.  Finally, the data 
are specific for the UK and the findings in terms of patterns of presentation 
and availability and use of treatment modalities are not necessarily applicable 
to other countries. It is likely, however, that similar issues are encountered 
internationally.  
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Conclusions 
This study suggests that severe poisoning with methanol and ethylene glycol 
is uncommon in the UK, but when this is encountered, difficulties are often 
experienced in confirming the diagnosis, in the sourcing and use of antidotes 
and in accessing haemodialysis when this is necessary. Most hospitals 
continue to rely on ethanol as an antidote, but problems in administration as 
well as adverse reactions are more commonly encountered with ethanol. As a 
consequence many patients require switching to fomepizole, but this is often 
not immediately available. 
 
Declaration of interest  
NPIS received a small unrestricted educational grant to undertake this study 
from EUSAPharma, the distributor of fomepizole in the UK.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
References 
 
1. Paasma R, Hovda KE, Tikkerberi A, Jacobsen D. Methanol mass poisoning 
in Estonia: outbreak in 154 patients. Clin Toxicol 2007; 45: 152-7. 
 
2. Ethylene glycol intoxication due to contamination of water systems. MMWR, 
Morb Mortal Wkly Rep 1987; 36: 611– 614.  
 
3. Jacobsen D, McMartin KE. Methanol and ethylene glycol poisonings: 
mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol 
1986; 1: 309-34.  
 
4.Thanacoody RHK, Aldridge G, Laing W, Dargan PI, Nash S, Thompson JP, 
Vale A, Bateman N, Thomas S. National audit of antidote stocking in acute 
hospitals in the UK. Emerg Med J 2013; 30:393-96.  
 
5. Persson HE , Sjöberg GK , Haines JA , De Garbino JP . Poisoning severity 
score . Grading of acute poisoning. J Toxicol Clin Toxicol 1998; 36: 205 – 213 
 
6. Coulter CV, Farquhar SE, Mcsherry CM, Isbister GK, Duffull SB. Methanol 
and ethylene glycol acute poisonings - Predictors of mortality. Clin Toxicol 
2011; 49:900-906. 
 
7. Paasma R, Hovda KE, Hassanian-Moghaddam H, Brahmi N, Afshari R, 
Sandvik L, Jacobsen D. Risk factors related to poor outcome after methanol 
 20 
poisoning and the relation between outcome and antidotes – A multicenter 
study. Clin Toxicol 2012; 50:823-31. 
 
8. Wedge MK, Natarajan S, Johanson C, Patel R, Kanji S. The safety of 
ethanol infusions for the treatment of methanol or ethylene glycol intoxication: 
an observational study. CJEM 2012; 14:283-89. 
 
9. Lepik KJ, Levy AR, Sobolev BG, Purssell RA, DeWitt CR, Erhardt GD, 
Kennedy JR, Daws DE, Brignall JL. Adverse drug events associated with 
the antidotes for methanol and ethylene glycol poisoning: a comparison of 
ethanol and fomepizole. Ann Emerg Med 2009; 53:439-50.e10.  
10. Grauer GF, Thrall MA, Henre BA, Hjelle JJ. Comparison of the effects of 
ethanol and 4-methylpyrazole on the pharmacokinetics and toxicity of 
ethylene glycol in the dog. Toxicol Lett 1987; 35: 307-14. 
11. Beatty L, Green R, Magee K, Zed P. A systematic review of ethanol and 
fomepizole use in toxic alcohol ingestions. Emerg Med Int 2013; 
2013:638057. 
12. Zakharov S, Pelclova D, Navratil T, Belacek J, Komarc M, Eddleston M, 
Hovda KE. Fomepizole versus ethanol in the treatment of acute methanol 
poisoning: Comparison of clinical effectiveness in a mass poisoning 
outbreak. Clin Toxicol 2015; 24: 1-10 
 21 
13. Levine M, Curry SC, Ruha A-M, Pizon AF, Boyer E, Burns J, Bikin D, 
Gerkin RD. Ethylene glycol elimination kinetics and outcomes in patients 
managed without hemodialysis. Ann Emerg Med 2012; 59:527-31.  
14. Darracq MA, Rentmeester LL, Clark RF, Tomaszewski CA, Schneir AB, 
Cantrell FL. Cost of hemodialysis versus fomepizole-only for treatment of 
ethylene glycol intoxication. Clin Toxicol 2013; 51:188.  
15. Thompson J, Watson I, Thanacoody H, Morley S, Thomas S, Eddleston 
M, Vale J, Bateman D, Krishna C. Guidelines for laboratory analyses for 
poisoned patients in the United Kingdom. Ann Clin Biochem 2014; 51: 312-25. 
 
 22 
Table 1. Characteristics and outcome of 204 patients requiring antidote treatment for ethylene glycol poisoning  
 2010 2012 Total Poisoning Severity Score (PSS) 
 at time of enquiry 
Plasma 
concentration 
Outcome 
Antidote 
treatment 
 
 
n 
(%)* 
 
 
n 
(%)* 
 
 
n 
(%)* 
0 
 
n 
(%)** 
1 
 
n 
(%)** 
2 
 
n 
(%)** 
3 
 
n 
(%)** 
Not 
Known 
n 
(%)** 
Detected 
Median (Range) 
mg/L 
Complete 
Recovery 
n 
(%)** 
Sequelae 
 
n 
(%)** 
Death 
 
n 
(%)** 
Not 
known 
n 
(%)** 
Ethanol only 44 
(47.8%) 
39 
(34.8%) 
83 
(40.7%) 
13 
(15.7%) 
31 
(37.3%) 
18 
(21.7%) 
18 
(21.7%) 
3 
(3.6%) 
29 
320 (14-2400) 
49 
(59.0%) 
6 
(7.2%) 
2 
(2.4%) 
26 
(31.3%) 
Fomepizole only 34 
(37.0%) 
47 
(42.0%) 
81 
(39.7%) 
7 
(8.6%) 
31 
(38.3%) 
13 
(16.0%) 
29 
(35.8%) 
1 
(1.2%) 
40 
725 (20-4614) 
52 
(64.2%) 
6 
(7.4%) 
3 
(3.7%) 
20 
(24.7%) 
Both ethanol and 
fomepizole 
14 
(15.2%) 
26 
(23.2%) 
40 
(19.6%) 
4 
(10%) 
11 
(27.5%) 
11 
(27.5%) 
14 
(35%) 
0 
(0%) 
30 
436 (32-3743) 
25 
(62.5%) 
5 
(12.5%) 
0 
(0%) 
10 
(25%) 
Ethanol oral only 6 
(6.5%) 
9 
(8.0%) 
15 
(7.4%) 
4 
(26.7%) 
8 
(53.3%) 
2 
(13.3%) 
1 
(67%) 
0 
(0%) 
4 
282 (32-2171) 
11 
(73.3%) 
0 
(0%) 
1 
(6.7%) 
3 
(20%) 
Ethanol iv only 31 
(33.7%) 
21 
(18.8%) 
52 
(25.5%) 
5 
(9.6%) 
15 
(28.8%) 
14 
(26.9%) 
15 
(28.8%) 
3 
(5.8%) 
18 
316 (14-2400) 
28 
(53.8%) 
4 
(7.7%) 
1 
(1.9%) 
19 
(36.5%) 
Ethanol  
(oral + iv) 
7 
(7.6%) 
9 
(8.0%) 
16 
(7.8%) 
4 
(25%) 
8 
(50%) 
2 
(12.5%) 
2 
(12.5%) 
0 
(0%) 
7 
320 (54-1250) 
10 
(62.5%) 
2 
(12.5%) 
0 
(0%) 
4 
(25%) 
Ethanol oral + 
Fomepizole 
3 
(3.3%) 
7 
(6.3%) 
10 
(4.9%) 
2 
(20%) 
4 
(40%) 
1 
(10%) 
3 
(30%) 
0 
(0%) 
7 
420 (32-3743) 
6 
(60%) 
0 
(0%) 
0 
(0%) 
4 
(40%) 
Ethanol iv + 
Fomepizole 
8 
(8.7%) 
16 
(14.3%) 
24 
(11.8%) 
1 
(4.2%) 
5 
(20.8%) 
7 
(29.2%) 
11 
(45.8%) 
0 
(0%) 
20 
402 (89-1584) 
13 
(54.2%) 
5 
(20.8%) 
0 
(0%) 
6 
(25%) 
Ethanol oral+ iv + 
Fomepizole 
3 
(3.3%) 
3 
(2.7%) 
6 
(2.8%) 
1 
(16.7%) 
2 
(33.3%) 
3 
(50%) 
0 
(0%) 
0 
(0%) 
3 
510 (150-2581) 
6 
(100%) 
0 
(%) 
0 
(%) 
0 
(%) 
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Table 2. Characteristics and outcome of 86 patients requiring extracorporeal treatment for ethylene glycol poisoning  
 
2010 2012 
Total 
Poisoning Severity Score (PSS) 
 at time of enquiry 
Plasma 
concentration 
Outcome 
Extracorporeal 
treatment 
 
 
 
n 
(%)* 
 
 
n 
(%)* 
 
 
n 
(%)* 
 
0 
 
n 
(%)** 
1 
 
n 
(%)** 
2 
 
n 
(%)** 
3 
 
n 
(%)** 
Not 
Known 
n 
(%)** 
Detected 
Median (Range) 
mg/L 
Complete 
Recovery 
n 
(%)** 
Sequelae 
 
n 
(%)** 
Death 
 
n 
(%)** 
Not 
known 
n 
(%)** 
Haemodialysis 15 
(48.4%) 
26 
(42.6%) 
41 
(44.6%) 
0 
(0%) 
8 
(22.2.5%) 
7 
(19.4%) 
26 
(58.3%) 
0 
(0%) 
30 
475 (14-4614) 
23 
(56.1%) 
10 
(24.4%) 
1 
(2.4%) 
7 
(17.1%) 
Haemodiafiltration 4 
(12.9%) 
12 
(19.7%) 
16 
(17.4%) 
0 
(0%) 
3 
(18.8%) 
2 
(12.5%) 
11 
(68.8%) 
0 
(0%) 
13 
307 (14-3743) 
10 
(62.5%) 
4 
(25%) 
0 
(0%) 
2 
(12.5%) 
Haemofiltration 12 
(38.7%) 
23 
(37.7%) 
35 
(38.0%) 
1 
(2.9%) 
5 
(14.3%) 
10 
(28.6%) 
18 
(51.4%) 
1 
(2.9%) 
22 
875 (20-2581) 
16 
(45.7%) 
8 
(22.9%) 
3 
(8.6%) 
8 
(22.9%) 
              
   *  % receiving each treatment modality in 2010, 2012 and both years. 
** % with each PSS score and outcome for each treatment modality 
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Table 3.   Prognostic factors in patients with ethylene glycol poisoning 
  Complete 
recovery 
n=129 
 Death or 
sequelae 
n=26 
   
 n=  n=    P 
Mean (±SD) age (years) 127 37 ± 13.7 26 47 ± 15.0   <0.001 
Poisoning Severity Score(PSS) 
mean (±SD) 
127 1.6 ± 1.0 26 2.5 ± 0.8   <0.0001 
Toxic alcohol concentration (mg/L) 
median (range) 
71 510 
(24-4614) 
19 654 
(14-2530) 
  ns 
Mean (±SD) pH on admission 100 7.26 ± 0.18 24 7.12 ± 0.21   0.001 
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Table 4.  Problems reported with ethanol and fomepizole use 
  Ethanol Fomepizole 
  n= n= 
Stocking 
 
Unavailable on site 
Inadequate stock to complete 
treatment 
3 
3 
16 
17 
Monitoring Ethanol concentrations not 
measured 
Sub-therapeutic ethanol 
concentrations 
6 
 
18 
N/A 
 
N/A 
Administration Difficulty in making infusion 
Difficulty calculating infusion 
rate 
Difficulty with reconstitution 
Dosing interval wrong 
Concomitant administration of 
both antidotes 
4 
4 
 
0 
N/A 
3 
N/A 
N/A 
 
1 
2 
3 
Inappropriate use Young children 
Teetotallers 
Ethnic and religious groups 
Severe ethanol intoxication 
before assay results available 
2 
2 
2 
2 
N/A 
N/A 
N/A 
N/A 
Discontinuation Too early leading to clinical 
deterioration 
2 0 
 26 
Figure 1  
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